TAX 327
from OncoPharm Hosted by John Bossaer
The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory. TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 14 minutes long.
When was this OncoPharm episode published?
This episode was published on September 17, 2020.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.